Summit Therapeutics Inc. Gain (Loss) on Disposition of Assets
Summit Therapeutics Inc. (SMMT) reported Gain (Loss) on Disposition of Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2026-02-23
- Summit Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2024-12-31 was $0.00.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2024-09-30 was $0.00.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2023-12-31 was -$2.00K.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for the quarter ending 2023-09-30 was -$11.00K.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2025 was $0.00.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2023 was $109.00K.
- Summit Therapeutics Inc. gain (loss) on disposition of assets for fiscal 2022 was $0.00.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 11 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-23 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $0.00 10-Q · filed 2024-10-30 | |||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 | ||||
| 2023-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$13.00K derived: sum of 2 quarters · filed 2026-02-23 | $109.00K 10-K · filed 2026-02-23 | ||
| 2023-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $111.00K 10-Q · filed 2024-10-30 | |||
| 2023-06-30 | $122.00K 10-Q · filed 2024-08-06 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $0.00 derived: sum of 2 quarters · filed 2025-02-24 | $0.00 10-K · filed 2025-02-24 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | ||||
| 2021-09-30 | -$2.00K 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$2.00K derived: sum of 2 quarters · filed 2021-11-15 | -$2.00K 10-K · filed 2021-03-31 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 8-K 6 month · filed 2021-11-15 | $0.00 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $0.00 8-K · filed 2020-09-29 | ||||
| 2019-12-31 | -$13.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | $1.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$33.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | -$34.00K 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | -$55.00K 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | -$54.00K 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |